BioArctic soars amid positive phase III results with lecanemab

After the controversies surrounding Biogen’s Aduhelm, the resignation has been palpable among the many Alzheimer’s patients who have been looking forward to an effective treatment for the disease. Now, there is new hope after Swedish BioArctic’s partner Eisai presented positive phase III results for the drug candidate lecanemab. The announcement caused BioArctic’s share to soar on the Swedish stock exchange, which also boosted sector colleagues Alzinova and AlzeCure.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/09/bioarctic-soars-amid-positive-phase-iii-results-with-lecanemab/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se